Clinical Trial

Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The sutdy aims to to demonstrate the non-inferiority of JP-1366 10 mg compared to Lanston Capsule 15 mg in preventing NSAIDs-induced peptic ulcers and to compare/evaluate the efficacy and safety of JP-1366 10 mg.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-05-29.
Status change: Not Yet Recruiting → Recruiting 2024-10-30
Trial Details
NCT Number NCT06439563
Lead Sponsor Onconic Therapeutics Inc.
Conditions Peptic Ulcer
Enrollment 364 participants
Start Date 2024-10-22
Primary Completion 2027-08 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2024-11-01